Utilization Management

Prior Authorization and Step Therapy Policies for Medicaid

Oncology (Oral - Epidermal Growth Factor Receptor Inhibitor) - Vizimpro PA Policy
Oncology (Oral - Fibroblast Growth Factor Receptor Agent) - Lytgobi PA Policy
Oncology (Oral - FMS-Like Tyrosine Kinase 3 Inhibitor) - Rydapt PA Policy
Oncology (Oral - FMS-Like Tyrosine Kinase 3 Inhibitor) - Vanflyta PA Policy
Oncology (Oral - FMS-Like Tyrosine Kinase 3 Inhibitor) - Xospata PA Policy
Oncology (Oral - Hedgehog Pathway Inhibitor) - Erivedge PA Policy
Oncology (Oral - Hedgehog Pathway Inhibitor) - Odomzo PA Policy
Oncology (Oral - Immunomodulator) - Lenalidomide PA Policy
Oncology (Oral - Immunomodulator) - Pomalyst PA Policy
Oncology (Oral - Immunomodulator) - Thalomid PA Policy
Oncology (Oral - Isocitrate Dehydrogenase 1 Inhibitor) - Rezlidhia PA Policy
Oncology (Oral - Isocitrate Dehydrogenase 1 Inhibitor) - Tibsovo PA Policy
Oncology (Oral - Kirsten RAt Sarcoma Virus Inhibitor) - Krazati PA Policy
Oncology (Oral - MEK Inhibitor) - Cotellic PA Policy
Oncology (Oral - MEK Inhibitor) - Mekinist PA Policy
Oncology (Oral - Neurotrophic Tyrosine Receptor Kinase Gene Fusion) - Augtyro PA Policy
Oncology (Oral - Neurotrophic Tyrosine Receptor Kinase Gene Fusion) - Rozlytrek PA Policy
Oncology (Oral - Neurotrophic Tyrosine Receptor Kinase Gene Fusion) - Vitrakvi PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Akeega PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Lynparza PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Rubraca PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Talzenna PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Zejula PA Policy
Oncology (Oral - Proteasome Inhibitor) - Ninlaro PA Policy
Oncology (Oral - Rearranged During Transfection-Targeting Agent) - Gavreto PA Policy
Oncology (Other) - Anktiva PA Policy
Ophthalmic - Glaucoma - Prostaglandins and Rho Kinase Inhibitors Policy
Ophthalmic - Glaucoma - Prostaglandins PA Policy Policy
Ophthalmic for Dry Eye Disease - Cyclosporine Products PA Policy Policy
Ophthalmic for Dry Eye Disease - Eysuvis PA Policy Policy
Ophthalmic for Dry Eye Disease - Xiidra PA Policy Policy
Ophthalmology - Dry Eye Disease - Cyclosporine Products PA Policy
Ophthalmology - Dry Eye Disease - Eysuvis PA Policy Policy
Ophthalmology - Dry Eye Disease - Lacrisert PA Policy Policy
Ophthalmology - Dry Eye Disease - Xiidra PA Policy
Ophthalmology - Dry Eye Disease – Miebo PA Policy
Ophthalmology - iDose TR PA Policy
Ophthalmology - iDose TR PA Policy
Ophthalmology - Izervay PA Policy
Ophthalmology - Izervay PA Policy
Ophthalmology - Oxervate PA Policy Policy
Ophthalmology - Syfovre PA Policy
Ophthalmology - Syfovre PA Policy
Ophthalmology - Vascular Endothelial Growth Factor Inhibitors - Susvimo PA Policy
Ophthalmology - Vascular Endothelial Growth Factor Inhibitors - Susvimo PA Policy
Ophthalmology - Vascular Endothelial Growth Factor Inhibitors - Vabysmo PA Policy
Ophthalmology - Vascular Endothelial Growth Factor Inhibitors - Vabysmo PA Policy
Ophthalmology - Verkazia PA Policy
Opioids - Fentanyl Transmucosal Drugs PA Policy Policy
Opioids - Long-Acting Products PA Policy Policy
Opioids - Methadone PA Policy
Opioids - Methadone Prior Authorization Policy Policy
Opioids - Tramadol Extended-Release Products PA Policy
Parkinson's Disease - Inbrija PA Policy Policy
Parkinson's Disease - Kynmobi PA Policy Policy
Parkinson's Disease - Nourianz PA Policy Policy
Parkinson's Disease - Tolcapone PA Policy
Parkinson’s Disease - Amantadine Extended-Release Drugs PA with Step Therapy Policy
Parkinson’s Disease - Apomorphine Subcutaneous PA Policy
Parkinson’s Disease - Nuplazid PA Policy Policy
Parkinson’s Disease - Vyalev PA Policy
Phenylketonuria - Palynziq PA Policy Policy
Phenylketonuria - Sapropterin (Kuvan) PA Policy Policy
Pheochromocytoma - Metyrosine and Phenoxybenzamine (Oral) PA Policy Policy
Pompe Disease - Enzyme Replacement Therapy - Pombiliti Prior Policy
Pompe Disease - Enzyme Replacement Therapy - Pombiliti Prior Policy
Pompe Disease - Enzyme Stabilization Therapy - Opfolda Prior Policy
Prader-Willi Syndrome - Vykat XR PA Policy
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors - Praluent PA Policy Policy
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors - Repatha PA Policy Policy
Psychiatry - Zurzuvae PA Policy
Pulmonary - Corticosteroid Long-Acting Beta2-Agonist Combination Inhalers PA Policy Policy
Pulmonary - Roflumilast PA with Step Therapy Policy Policy
Pulmonary - Roflumilast Prior Authorization with Step Therapy Policy Policy
Pulmonary – Short-Acting Beta2-Agonist Inhalers Policy
Pulmonary Arterial Hypertension - Adempas PA Policy Policy
Pulmonary Arterial Hypertension - Endothelin Receptor Antagonist PSM Policy Policy
Pulmonary Arterial Hypertension - Orenitram PA Policy Policy
Pulmonary Arterial Hypertension - Phosphodiesterase Type 5 Inhibitors PA Policy Policy
Pulmonary Arterial Hypertension - Uptravi PA Policy Policy
Pulmonary Arterial Hypertension - Winrevair PA Policy
Repository Corticotropin - Acthar Gel PA Policy Policy
Repository Corticotropin - Cortrophin Gel PA Policy
Sickle Cell Disease - Endari PA Policy Policy
Sickle Cell Disease - Oxbryta PA Policy Policy
Sohonos PA Policy
Somatostatin Analogs - Lanreotide Products PA Policy
Somatostatin Analogs - Octreotide Immediate-Release Products PA Policy Policy
Somatostatin Analogs - Octreotide Long-Acting Products PA Policy
Somatostatin Analogs - Somatuline Depot PA Policy Policy
Somavert PA Policy Policy
Tasimelteon Products PA Policy
Testosterone (Oral, Topical, and Nasal) Products PA Policy Policy
Thrombocytopenia - Doptelet PA Policy Policy
Thrombocytopenia - Eltrombopag Products PA Policy
Thrombocytopenia - Eltromboppag Products PA Policy
Tolvaptan Products - Tolvaptan (Samsca) PA Policy Policy
Topical Acyclovir Products PA Policy Policy
Topical Diclofenac Sodium 3% Gel PA Policy
Topical Retinoids - Aklief PA Policy Policy